Patritumab deruxtecan (HER3-DXd)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-PATRITUMAB-DERUXTECAN |
|---|---|
| Type | Drug |
| Aliases | Патритумаб дерукстекан |
| Status | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | HER3-targeted antibody-drug conjugate (deruxtecan / topo-I inhibitor payload) |
|---|---|
| Mechanism | Fully human anti-HER3 (ERBB3) IgG1 monoclonal antibody linked to deruxtecan (DXd, exatecan-derivative topoisomerase-I inhibitor) via cleavable tetrapeptide linker. Drug-to-antibody ratio ~8:1 with bystander effect. HER3 is broadly expressed across solid tumors and frequently upregulated as a resistance mechanism after EGFR TKI in EGFR-mutant NSCLC. |
| Typical dosing | 5.6 mg/kg IV q3 weeks until disease progression or unacceptable toxicity (HERTHENA-Lung01 schedule). Premedicate with antiemetics; high-emetogenicity prophylaxis recommended. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-29 |
Notes
HERTHENA-Lung01 (NCT04619004): Phase II, EGFR-mutated metastatic NSCLC after EGFR TKI + platinum-based chemo. ORR 29.8%, mPFS 5.5 mo, mOS 11.9 mo. Filed for FDA accelerated approval Dec 2023; CRL received Jun 2024 (third-party manufacturing issue, not efficacy/safety). Distinct AE profile vs other DXd ADCs: cytopenias more prominent than ILD. Status as of 2026-04: investigational only; not commercially available. Trial-source SRC for HERTHENA-Lung01 not yet ingested into KB — FLAG for follow-up.
Used By
Regimens
REG-PATRITUMAB-DXD-NSCLC-POST-EGFR- Patritumab deruxtecan monotherapy (HERTHENA-Lung01) — EGFR-mutant NSCLC post-osimertinib...